Dermavant to Present New ADORING Data Including Treatment of Patients with Skin of Color from Phase 3 Trials of VTAMA® (tapinarof) Cream, 1% in Adults and Children 2 Years of Age and Older with Atopic Dermatitis at the 2024 AAD Annual Meeting

LONG BEACH, Calif. & BASEL, Switzerland–(BUSINESS WIRE)–Dermavant to Present New ADORING Data at the 2024 American Academy of Dermatology Annual Meeting
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks